Endogenic PharmacologyThe Canonical Reference
Delivery Platforms · Oral and Mucosal Delivery

Intranasal Nose-to-Brain Delivery

Intranasal delivery that bypasses the blood-brain barrier through the olfactory and trigeminal pathways for CNS-targeted bioregulators.

The Atumnus Olfactrix™ Platform

Definition

Intranasal delivery that bypasses the blood-brain barrier through the olfactory and trigeminal pathways for CNS-targeted bioregulators.

Full mechanistic definition forthcoming.


Pharmaceutical History

A documented format in pharmaceutical practice.

Historical timeline of the delivery format in the pharmaceutical literature — first characterization, commercial precedents, decades of regulatory-approved use — forthcoming.


Mechanism and Pharmacokinetics

How the format delivers.

Absorption pathway, bioavailability characteristics, first-pass metabolism considerations, onset and duration profiles — forthcoming.


Applicable Compounds

Bioregulators formulated for this platform.

Tetrapeptide-AEDG, Tripeptide-EDR, and selected acetylated and amidated analogs for direct nose-to-brain delivery.

See the full bioregulator class and the per-compound published literature for compound-specific research references.


Regulatory Pathway

Classification and oversight.

Dietary supplement, OTC monograph (limited claims), 503A compounding, and NDA pathways depending on indication and dose.

Detailed regulatory analysis — agency-specific requirements, classification thresholds, and pathway-specific labeling considerations — forthcoming.


Peer-Reviewed Foundation

The format in the scientific literature.

PubMed-indexed peer-reviewed references establishing the format as legitimate pharmaceutical science — forthcoming.


The Atumnus Implementation

The Atumnus Olfactrix™ platform.

The Olfactrix™ platform is the Atumnus patent-pending embodiment of Intranasal Nose-to-Brain Delivery. It is licensed to operating affiliates for commercial development across the Opticeutical and Endoceutical tiers, and is one of the branded delivery technologies that anchors the Atumnus intellectual-property estate.

The Olfactrix™ trademark and associated patent-pending technology are held by Atumnus LLC, the founding entity of endogenic pharmacology. See affiliated entities for institutional structure.


Related Platforms

Adjacent delivery formats.

Within the same cluster (Oral and Mucosal Delivery), see the full set of delivery platforms in this category.

← Back to all delivery platforms